A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

In a year when eradicated diseases are on the uptick in America, how will American children survive RFK Jr.’s vaccine ...

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

Govorestat failed to meet its primary endpoint in a Phase II/III trial for a rare form of Charcot-Marie-Tooth disease, a few ...

Taking center stage at the American Society of Gene and Cell Therapy meeting was the first-ever reported case of a ...

The restrictions on Novavax's vaccine could portend changes at the FDA. Commissioner Marty Makary suggested last week that ...